<?xml version="1.0" encoding="UTF-8"?>
<p id="Par62">Many mAbs are under development for treatment of infectious diseases, currently only four have been approved by the US FDA: raxibacumab and obiltoxaximab for treatment of inhalational anthrax [
 <xref ref-type="bibr" rid="CR63">63</xref>], palivizumab for prevention of respiratory syncytial virus in high-risk infants [
 <xref ref-type="bibr" rid="CR64">64</xref>], and ibalizumab for treatment of HIV infection patients [
 <xref ref-type="bibr" rid="CR65">65</xref>]. Ibalizumab (Trogarzo) is a humanized IgG4 mAb that is used as a CD4 domain 2-directed post-attachment HIV-1 inhibitor. The US FDA approved ibalizumab for adult patients infected with HIV who were previously treated and are resistant to currently available therapies.
</p>
